Overview

Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

Phase II trial of Neoadjuvant [FEC100]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer

Phase:

N/A

Details

Lead Sponsor:

King Faisal Specialist Hospital & Research Center

Treatments:

Cisplatin
Docetaxel
Trastuzumab